dc.contributor.author
Meisel, Andreas
dc.contributor.author
Baggi, Fulvio
dc.contributor.author
Behin, Anthony
dc.contributor.author
Evoli, Amelia
dc.contributor.author
Kostera‐Pruszczyk, Anna
dc.contributor.author
Mantegazza, Renato
dc.contributor.author
Morales, Raul Juntas
dc.contributor.author
Punga, Anna Rostedt
dc.contributor.author
Sacconi, Sabrina
dc.contributor.author
Schroeter, Michael
dc.contributor.author
Verschuuren, Jan
dc.contributor.author
Crathorne, Louise
dc.contributor.author
Holmes, Kris
dc.contributor.author
Leite, Maria‐Isabel
dc.date.accessioned
2025-03-24T11:22:27Z
dc.date.available
2025-03-24T11:22:27Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/46994
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-46709
dc.description.abstract
Background and purpose
Although myasthenia gravis (MG) is recognized as an immunoglobulin G autoantibody-mediated disease, the relationship between autoantibody levels and disease activity in MG is unclear. We sought to evaluate this landscape through systematically assessing the evidence, testing the impact of predefined variables on any relationship, and augmenting with expert opinion.
Methods
In October 2020, a forum of leading clinicians and researchers in neurology from across Europe (Expert Forum for Rare Autoantibodies in Neurology in Myasthenia Gravis) participated in a series of virtual meetings that took place alongside the conduct of a systematic literature review (SLR).
Results
Forty-two studies were identified meeting inclusion criteria. Of these, 10 reported some correlation between a patient's autoantibody level and disease severity. Generally, decreased autoantibody levels (acetylcholine receptor, muscle-specific kinase, and titin) were positively and significantly correlated with improvements in disease severity (Quantitative Myasthenia Gravis score, Myasthenia Gravis Composite score, Myasthenia Gravis Activities of Daily Living score, Myasthenia Gravis Foundation of America classification). Given the limited evidence, testing the impact of predefined variables was not feasible.
Conclusions
This first SLR to assess whether a correlation exists between autoantibody levels and disease activity in patients with MG has indicated a potential positive correlation, which could have clinical implications in guiding treatment decisions. However, in light of the limited and variable evidence, we cannot currently recommend routine clinical use of autoantibody level testing in this context. For now, patient's characteristics, clinical disease course, and laboratory data (e.g., autoantibody status, thymus histology) should inform management, alongside patient-reported outcomes. We highlight the need for future studies to reach more definitive conclusions on this relationship.
en
dc.rights.uri
https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject
autoantibodies
en
dc.subject
myasthenia gravis
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Role of autoantibody levels as biomarkers in the management of patients with myasthenia gravis: A systematic review and expert appraisal
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.doi
10.1111/ene.15565
dcterms.bibliographicCitation.journaltitle
European Journal of Neurology
dcterms.bibliographicCitation.number
1
dcterms.bibliographicCitation.originalpublishername
Wiley
dcterms.bibliographicCitation.pagestart
266
dcterms.bibliographicCitation.pageend
282
dcterms.bibliographicCitation.volume
30
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.funding
DEAL Wiley
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
36094738
dcterms.isPartOf.issn
1351-5101
dcterms.isPartOf.eissn
1468-1331